Press Releases

Second quarter total revenue is estimated to be $126.7 million , a 21% increase over 2019 Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million , an 11% increase over 2019 Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 Management to host a
Posted: August 11, 2020
First quarter total revenue of $95.0 million , an 11% increase over 2019 First quarter net product sales of $92.5 million , an 11% increase over 2019 First quarter operating earnings of $29.0 million , a 14% increase over 2019 On track for launch of SPN-812 at the end of 2020, pending FDA approval.
Posted: May 5, 2020
  Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipeline Diversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million and operating earnings of $45 million Enhances long term growth with po tential launch of
Posted: April 28, 2020
ROCKVILLE, Md. , March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to the COVID-19
Posted: March 30, 2020
Displaying 1 - 10 of 15